Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer: a real-world study
Q Zhong, Z Liu - Cancer Management and Research, 2021 - Taylor & Francis
Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
Q Zhong, Z Liu - Cancer Management and Research, 2021 - search.proquest.com
Background: Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
Q Zhong, Z Liu - Cancer Management and Research, 2021 - dovepress.com
Background: Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
[HTML][HTML] Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
Q Zhong, Z Liu - Cancer Management and Research, 2021 - ncbi.nlm.nih.gov
Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
Q Zhong, Z Liu - Cancer management and research, 2021 - pubmed.ncbi.nlm.nih.gov
Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Q Zhong, Z Liu - Cancer Management and Research, 2021 - go.gale.com
Background: Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Q Zhong, Z Liu - Cancer Management and Research, 2021 - europepmc.org
Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …